(PharmaNewsWire.Com, June 03, 2017 ) The G8 Generics industry guide provides top-line qualitative and quantitative summary information including: market size (value and volume 2011-15, and forecast to 2020). The guide also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
-Save time carrying out entry-level research by identifying the size, growth, and leading players in the G8 generics market
-Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the G8 generics market
-Leading company profiles reveal details of key generics market players' G8 operations and financial performance
-Add weight to presentations and pitches by understanding the future growth prospects of the G8 generics market with five year forecasts
-Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country
Highlights
The G8 countries contributed $142.9 billion in 2015 to the global generics industry, with a compound annual growth rate (CAGR) of 6% between 2011 and 2015. The G8 countries are expected to reach a value of $188.6 billion in 2020, with a CAGR of 5.7% over the 2015-20 period.
Among the G8 nations, the US is the leading country in the generics industry, with market revenues of $94.0 billion in 2015. This was followed by Japan and Russia, with a value of $10.2 and $10.0 billion, respectively.
The US is expected to lead the generics industry in the G8 nations with a value of $128.0 billion in 2016, followed by Russia and Japan with expected values of $15.9 and $11.9 billion, respectively.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: